In checkpoint therapy, antibodies bind to molecules involved in T-cell regulation to remove inhibitory pathways that block T-cell responses, known as immune checkpoint therapy [REF].
In 2016, researchers developed a technique that used cancer cells' RNA to produce T cells and an immune response.